Emergent BioSolutions says it can make 1 billion Covid vaccine doses annually

Date Published03/03/2021
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Emergent BioSolutions
Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2021
Year reshoring implemented or to be implemented:2021
Domestically, the work will be done:In-house
City reshored to:Gaithersburg
State(s) reshored to:MD
If relevant, work nearshored to:-
Product(s) reshoredAstraZeneca & Johnson & Johnson Covid-19 vaccines
What domestic positive factors made reshoring more attractive?Infrastructure, Under-utilized capacity, Other, Covid-19, import replacement
Find Reshoring Articles